

NDA 216185

**NOTIFICATION OF
NON-COMPLIANCE WITH PREA**

Aucta Pharmaceuticals, Inc.
Attention: Yujin Bi
Director, Regulatory Affairs
170 Mt Airy Rd
Basking Ridge, NJ 07920

Dear Yujin Bi:

Please refer to your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Motpoly XR (lacosamide) capsule, which was approved on May 4, 2023.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for the following:

PMR 4437-1, which was deferred until March 31, 2026.

Under the provisions of section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 355c(d)(1)], you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a **“DEFERRAL EXTENSION REQUESTED”** in your response. We note that you requested a deferral extension on December 29, 2025; however, we have determined that your request did not qualify for an extension.

In accordance with the FD&C Act, FDA will post this letter and your response to the website at <https://www.fda.gov/drugs/development-resources/non-compliance-letters-under-505bd1-federal-food-drug-and-cosmetic-act> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a **“RESPONSE TO PREA NON-COMPLIANCE LETTER.”** To facilitate our review, submit this information to your NDA with a cross-reference letter to the investigational new drug application (IND) to which your protocol has been submitted.

If you have any questions, contact Kelly Ross, Pharm.D., BCPS, Regulatory Project Manager, at Kelly.Ross@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Emily Freilich, MD
Director
Division of Neurology 1
Office of Neuroscience
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

EMILY R FREILICH
04/28/2026 10:40:48 AM
On behalf of DN2